[1] |
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
|
[2] |
REVILL PA, CHISARI FV, BLOCK JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7): 545-558. DOI: 10.1016/S2468-1253(19)30119-0.
|
[3] |
LIAO H, LIU Y, LI X, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy[J]. Antivir Ther, 2019, 24(2): 105-115. DOI: 10.3851/IMP3280.
|
[4] |
WANG J, YU Y, LI G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients[J]. J Hepatol, 2017. DOI: 10.1016/j.jhep.2017.08.021.
|
[5] |
HATAKEYAMA T, NOGUCHI C, HIRAGA N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine[J]. Hepatology, 2007, 45(5): 1179-1186. DOI: 10.1002/hep.21581.
|
[6] |
JANSEN L, KOOTSTRA NA, van DORT KA, et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues[J]. J Infect Dis, 2016, 213(2): 224-232. DOI: 10.1093/infdis/jiv397.
|
[7] |
van BÖMMEL F, BARTENS A, MYSICKOVA A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology, 2015, 61(1): 66-76. DOI: 10.1002/hep.27381.
|
[8] |
LUO H, ZHANG XX, CAO LH, et al. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients[J]. World J Gastroenterol, 2019, 25(6): 719-728. DOI: 10.3748/wjg.v25.i6.719.
|
[9] |
Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B[J]. J Clin Hepatol, 2006, 22(1): 3-15. http://lcgdbzz.org/article/id/LCGD200601000
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 临床肝胆病杂志, 2006, 22(1): 3-15. http://lcgdbzz.org/article/id/LCGD200601000
|
[10] |
WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710. DOI: 10.1016/j.jhep.2016.05.029.
|
[11] |
HUANG H, WANG J, LI W, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals[J]. J Clin Virol, 2018, 99-100: 71-78. DOI: 10.1016/j.jcv.2017.12.016.
|
[12] |
BLAND JM, ALTMAN DG. Statistical methods for assessing agreement between two methods of clinical measurement[J]. Lancet, 1986, 1(8476): 307-310.
|
[13] |
LILJEQUIST D, ELFVING B, SKAVBERG ROALDSEN K. Intraclass correlation - A discussion and demonstration of basic features[J]. PLoS One, 2019, 14(7): e0219854. DOI: 10.1371/journal.pone.0219854.
|
[14] |
Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
|
[15] |
European Association for the Study of the Liver, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398. DOI: 10.1016/j.jhep.2017.03.021.
|
[16] |
FAN R, ZHOU B, XU M, et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 719-727. e7. DOI: 10.1016/j.cgh.2019.07.046.
|
[17] |
WANG X, WANG Z, CHI X, et al. Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks[J]. Int J Infect Dis, 2020, 99: 171-178. DOI: 10.1016/j.ijid.2020.07.031.
|
[18] |
CHEN EQ, WANG ML, TAO YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat, 2019, 26(5): 586-595. DOI: 10.1111/jvh.13061.
|
[19] |
WANG J, DU M, HUANG H, et al. Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity": Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B[J]. J Hepatol, 2017, 66(2): 462-463. DOI: 10.1016/j.jhep.2016.10.034.
|